Article
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
BMC cancer - 9 Aug 2012
Reinacher-Schick Anke, Schulmann Karsten, Modest Dominik P, Bruns Nina, Graeven Ulrich, Jaworska Malgorzata, Greil Richard, Porschen Rainer, Arnold Dirk, Schmiegel Wolff, Tannapfel Andrea
Abstract excerpt
BACKGROUND: To evaluate the value of KRAS codon 13 mutations in patients with advanced colorectal cancer (advanced CRC) treated with oxaliplatin and fluoropyrimidines. METHODS: Tumor specimens from 201 patients with advanced CRC from a randomized, phase III trial comparing oxaliplatin/5-FU vs. ox...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.